Work

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study

Year: 2016

Type: article

Study design: Clinical Trial

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2016.04.038

Authors: S.N. Westin, M. Sill, R.L. Coleman, S.E. Waggoner, K.N. Moore, C.A. Mathews, A. Jain, S.C. Modesitt, R. Schilder, C. Aghajanian

Institutions: The University of Texas MD Anderson Cancer Center, University Hospitals Cleveland Medical Center, University of Oklahoma, Brown University, Fox Chase Cancer Center, University of Virginia Health System, Thomas Jefferson University, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2466440584

FWCI: 1.147

Cites:

Cited by: 6

Related to: 10